Investigator Perspectives on Emerging Concepts in the Management of Genitourinary CancersHER2-positive bladder cancer
1:33 minutes.
TRANSCRIPTION:
DR PETRYLAK: It’s actually a little more frequent than people realized. Maha Hussain and I published a paper a number of years ago looking at HER2/neu expression in metastatic disease. And that seemed to correlate with the poor prognostic factors such as liver metastases and bone metastases. We actually looked at the combination of trastuzumab/carboplatin/paclitaxel and gemcitabine. Had a survival rate that was similar to what we saw in some of the other Phase II trials with gem/cis alone. But remember, again, that was a poorer-prognosis group of patients, and, unfortunately, that never was followed up on. DR LOVE: But again, what fraction of bladder cancer is HER2-positive, roughly? DR PETRYLAK: It’s about 30%. DR LOVE: Really? And have anti-HER therapy — you mentioned the one study, but any other trials? DR PETRYLAK: Tom Powles did a randomized study of lapatinib postchemotherapy. This was a randomized trial. Patients received 4 to 8 cycles of chemotherapy and then went on lapatinib maintenance. And unfortunately, it didn’t show any improvement in progression-free or overall survival. There have been some Phase II trials that have been performed in the second line, but nothing that’s really been showing significant activity. DR LOVE: That's interesting. At the last ASCO meeting, there was a paper in colon cancer, metastatic, HER2-positive, which is very uncommon, where they saw pretty good responses to lapatinib/trastuzumab. Has that been tried in bladder cancer? DR PETRYLAK: That’s not been tried, to my knowledge. |